Drugs / IVW-1001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT06400459 | Jun → Oct 2024 | dry eye syndrome | IVIEW Therapeutics Inc. | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT07161011 | Sep → Nov 2025 | dry eye syndrome | IVIEW Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07140380 | Aug → Oct 2025 | dry eye syndrome | IVIEW Therapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | IVIEW Therapeutics Inc. | Results IVIEW Therapeutics Showcases Robust Pipeline at Eyecelerator and ARVO 2026, Highlighting Clinical Advances in Dry Eye, Viral Conjunctivitis, Glaucoma Gene Therapy, and Ocular Inflammation Treatment iviewtherapeutics.com ↗
The presentation showcased clinical data demonstrating that IVW-1001, a first-in-class TRPM8 agonist delivered via a proprietary eyelid wipe, achieved statistically significant improvements in both signs and symptoms of dry eye disease (DED) with a favorable safety profile (0–3% ocular irrit |
| 2025-10-21 | IVIEW Therapeutics Inc. | Results IVIEW Therapeutics’ Dry Eye Disease Research Featured in Two ReachMD Podcasts Following AAO 2025 Presentation iviewtherapeutics.com ↗
The second episode, “Evaluating Eyelid Wipes for Dry Eye Disease: Clinical Trial Insights,” detailed the design and results of IVIEW’s proof-of-concept study, which demonstrated promising efficacy and safety outcomes across both signs and symptoms of Dry Eye Disease. |
| 2025-05-08 | IVIEW Therapeutics Inc. | Results IVIEW Therapeutics’ CEO Dr. Bo Liang chaired a Roundtable at the First International Alliance for Ophthalmology Innovation (IOAI) Forum iviewtherapeutics.com ↗
The IVW-1001 project, a NCE innovative drug with a novel target TRPM8 agonist for the treatment of dry eye disease (DED) has completed the Phase 1/2 clinical trials and achieved positive top-line results. |
| 2024-03-08 | IVIEW Therapeutics Inc. | Regulatory IVIEW Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease iviewtherapeutics.com ↗
iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical trial as safe to proceed. |
| 2023-01-30 | IVIEW Therapeutics Inc. | Regulatory IVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease iviewtherapeutics.com ↗
January 30, 2023 iVIEW Therapeutics Inc., a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics, today announced that the company completed a successful pre-IND meeting with FDA and received the agency’s full agreement on all CMC, non-clinical and clinical development plans to develop IVW-1001 for the treatment of sign and symptoms of dry eye disease (DED). |
All press releases naming this drug 11 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVW 1001 | “Treatments will be IVW-1001 Ophthalmic Eyelid Wipe 0.2% (high dose), IVW 1001 0.1% (low dose), or IVW-1001 Ophthalmic Eyelid Wipe Placebo (vehicle).” NCT06400459 ↗ |
| Route | Topical | “wipe upper eyelid in a nasal to temporal direction with the IVW-1001 Ophthalmic Eyelid Wipe” NCT07140380 ↗ |